Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Jurk
Marion
M
Heil
Florian
F
Vollmer
Jörg
J
Schetter
Christian
C
Krieg
Arthur M
AM
Wagner
Hermann
H
Lipford
Grayson
G
Bauer
Stefan
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D029721:Drosophila Proteins; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D051199:Toll-Like Receptor 7; D051200:Toll-Like Receptor 8; D051193:Toll-Like Receptors; D014162:Transfection
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D029721:Drosophila Proteins; D007093:Imidazoles; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D011956:Receptors, Cell Surface; C495348:TLR7 protein, human; C495349:TLR8 protein, human; D051199:Toll-Like Receptor 7; D051200:Toll-Like Receptor 8; D051193:Toll-Like Receptors; C402365:resiquimod